Results 211 to 220 of about 66,322 (227)

The Risk of Arterial Thrombosis in Patients With Chronic Myeloid Leukemia Treated With Second and Third Generation BCR-ABL Tyrosine Kinase Inhibitors May Be Explained by Their Impact on Endothelial Cells: An In-Vitro Study

Frontiers in Pharmacology, 2020
Hélène Haguet, Pierre Sonveaux, Jonathan Douxfils   +2 more
exaly  

Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia

Nature Reviews Cancer, 2007
Andreas Hochhaus
exaly  

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl

Cancer Cell, 2005
Ellen Weisberg, Paul W Manley, Brian J P Huntly   +2 more
exaly  

Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy

Journal of Hematology and Oncology, 2018
Federico Rossari, Filippo Minutolo, Enrico Orciuolo   +2 more
exaly  

BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia

Frontiers in Oncology, 2019
Sara Galimberti, Antonio Curti, Alessandro Isidori   +2 more
exaly  

Requirement for CD44 in homing and engraftment of BCR-ABL–expressing leukemic stem cells

Nature Medicine, 2006
Daniela S Krause
exaly  

Mechanisms of Autoinhibition and STI-571/Imatinib Resistance Revealed by Mutagenesis of BCR-ABL

Cell, 2003
George Q Daley
exaly  

AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL

British Journal of Cancer, 2006
Heide Spiegel
exaly  

Allosteric inhibitors of Bcr-abl–dependent cell proliferation

Nature Chemical Biology, 2006
Paul W Manley
exaly  

BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia

Nature Chemical Biology, 2012
Oliver Hantschel, Florian Grebien, Kay-uwe Wagner   +2 more
exaly